

Appendix 4
(just front page)



US005874540A

United States Patent [19]

Hansen et al.

[11] Patent Number: 5,874,540

[45] Date of Patent: Feb. 23, 1999

[54] CDR-GRAFTED TYPE III ANTI-CEA
HUMANIZED MOUSE MONOCLONAL
ANTIBODIES

[75] Inventors: Hans J. Hansen, Mystic Island, N.J.;
Kathryn L. Armour, Aberdeen,
Scotland

[73] Assignee: Immunomedics, Inc., Morris Plains,
N.J.

[21] Appl. No.: 318,177

[22] Filed: Oct. 1, 1994

[51] Int. Cl.⁶ C07K 16/46; C12N 15/13;
C07H 21/04

[52] U.S. Cl. 530/387.3; 530/388.85;
530/388.8; 530/391.7; 530/391.3; 536/23.53;
435/28; 435/69.7; 435/320.1; 424/1.49;
424/178.1; 424/181.1

[58] Field of Search 530/307.1, 388.8,
530/391.7, 391.3, 387.3, 388.85; 424/130.1,
138.1, 1.49, 178.1, 181.1; 536/23.53; 435/328,
69.7, 320.1

[56] References Cited

U.S. PATENT DOCUMENTS

4,818,709 4/1989 Primus et al. 436/518
5,081,235 1/1992 Shively et al. 536/27
5,530,101 6/1996 Queen et al. 530/387.3

FOREIGN PATENT DOCUMENTS

0 239 400 9/1987 European Pat. Off. C12N 15/00

0 323 805 A2 7/1989 European Pat. Off.
0 323 806 12/1989 European Pat. Off.
92/01059 1/1992 WIPO C12P 21/08
WO 92/01059 1/1992 WIPO

OTHER PUBLICATIONS

Primus et al., "Immunological Heterogeneity of Carcinoembryonic . . .", *Cancer Research*, 43:686-92, Feb. 1983.
Hansen et al., "Characterization of Second-Generation Monoclonal . . .", *Cancer*, 71(11):3478-85, Jun. 1993.
Losman et al., "Mimicry of a Carcinoembryonic Antigen Epitope . . .", *In. J. Cancer*, 56:580-84, 1994.
Sharkey et al. [*Cancer* 71(6):2082-2096 (1993)].
Riechmann et al. [*Nature* 332:323-327 (1988)].
Queen et al. [*PNAS* 86:10029-10033 (1989)].
Blumenthal et al. [*Cancer Res* 52(21):6036-6044 (1992)].

Primary Examiner—Frank C. Eisenschien
Attorney, Agent, or Firm—Foley & Lardner

[57]

ABSTRACT

A humanized monoclonal antibody, comprising the complementarity-determining regions of a parental murine Class III, anti-CEA monoclonal antibody engrafted to the framework regions of a heterologous antibody, wherein the humanized monoclonal antibody retains the binding specificity of, but is less immunogenic in a heterologous host than, the parental murine monoclonal antibody. A preferred murine Class III, anti-CEA monoclonal antibody is the MN-14 antibody and the preferred heterologous antibody is from a human. Also provided are DNA constructs and vectors for producing the humanized monoclonal antibodies, and diagnostic and therapeutic conjugates using same.

30 Claims, 16 Drawing Sheets